Comprehensive Characterization of Intraductal Oncocytic Papillary Neoplasm of the Pancreas: a systematic and critical review

Gaetano Paolino, Olca Basturk, Irene Esposito, Seung-Mo Hong, Lodewijk A Brosens, Zeynep Tarcan, Laura D Wood, Anastasios Gkountakos, Yuko Omori, Paola Mattiolo, Calogero Ciulla, Giovanni Marchegiani, Antonio Pea, Michele Bevere, Riccardo De Robertis, Mirko D'Onofrio, Roberto Salvia, Liang Cheng, Toru Furukawa, Aldo ScarpaVolkan Adsay, Claudio Luchini*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

Intraductal oncocytic papillary neoplasm (IOPN) of the pancreas is a recently recognized pancreatic tumor. Here, we aimed to determine its most essential features with the systematic review tool. PubMed, Scopus, and Embase were searched for studies reporting data on pancreatic IOPN. The clinicopathologic, immunohistochemical, and molecular data were extracted and summarized. Then, a comparative analysis of the molecular alterations of IOPN with those of pancreatic ductal adenocarcinoma and intraductal papillary mucinous neoplasm from reference cohorts (including The Cancer Genome Atlas) was conducted. The key findings from 414 IOPNs were as follows: 1) The male-to-female ratio was 1.5:1. Pancreatic head was the most common site (131/237; 55.3%), but a diffuse tumor extension involving more than one pancreatic segment was described in about 1 out of 5 cases (49/237; 20.6%). The mean size was 45.5 mm. An associated invasive carcinoma was present in 50% of cases (168/336). In those cases, most tumors were pT1 or pT2 and pN0 (>80%), and vascular invasion was uncommon (20.6%). Regarding survival, more than 90% of patients were alive after surgical resection. 2) Immunohistochemical and molecular features were as follows. The most commonly expressed mucins were MUC5AC (110/112; 98.2%) and MUC6 (78/84; 92.8%). Compared with pancreatic ductal adenocarcinoma and intraductal papillary mucinous neoplasm, the classic pancreatic drivers KRAS, TP53, CDKN2A, SMAD4, and GNAS were less altered in IOPN (P < .01). Moreover, fusions involving PRKACA or PRKACB gene were detected in all of the 68 cases examined, with PRKACB::ATP1B1 being the most common (27/68 cases; 39.7%). These genomic events emerged as an entity-defining molecular alteration of IOPN (P < .01). Thus, such fusions represent a promising biomarker for diagnostic purposes. Recent evidence also suggests their role in influencing the acquisition of oncocytic morphology. IOPN is a distinct pancreatic neoplasm with specific clinicopathologic and molecular features.

Original languageEnglish
Article number100554
JournalModern Pathology
Volume37
Issue number9
Early online date29 Jun 2024
DOIs
Publication statusPublished - Sept 2024

Keywords

  • intraductal
  • intraductal oncocytic papillary neoplasm
  • intraductal papillary mucinous neoplasm
  • oncocytic
  • oxyphilic
  • pancreatic cancer
  • PRKACA
  • PRKACB

Fingerprint

Dive into the research topics of 'Comprehensive Characterization of Intraductal Oncocytic Papillary Neoplasm of the Pancreas: a systematic and critical review'. Together they form a unique fingerprint.

Cite this